- Home
- CGNT vs TRVI Comparison
CGNT vs TRVI Comparison
Compare CGNT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- TRVI
- Stock Information
- Founded
- CGNT 2020
- TRVI 2011
- Country
- CGNT Israel
- TRVI United States
- Employees
- CGNT N/A
- TRVI N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- TRVI Health Care
- Exchange
- CGNT Nasdaq
- TRVI Nasdaq
- Market Cap
- CGNT 657.1M
- TRVI 725.7M
- IPO Year
- CGNT N/A
- TRVI 2019
- Fundamental
- Price
- CGNT $8.46
- TRVI $8.07
- Analyst Decision
- CGNT Hold
- TRVI Strong Buy
- Analyst Count
- CGNT 1
- TRVI 9
- Target Price
- CGNT N/A
- TRVI $20.72
- AVG Volume (30 Days)
- CGNT 289.4K
- TRVI 2.9M
- Earning Date
- CGNT 09-09-2025
- TRVI 11-05-2025
- Dividend Yield
- CGNT N/A
- TRVI N/A
- EPS Growth
- CGNT N/A
- TRVI N/A
- EPS
- CGNT N/A
- TRVI N/A
- Revenue
- CGNT $376,566,000.00
- TRVI N/A
- Revenue This Year
- CGNT $14.94
- TRVI N/A
- Revenue Next Year
- CGNT $9.57
- TRVI N/A
- P/E Ratio
- CGNT N/A
- TRVI N/A
- Revenue Growth
- CGNT 14.04
- TRVI N/A
- 52 Week Low
- CGNT $6.38
- TRVI $2.36
- 52 Week High
- CGNT $11.66
- TRVI $9.92
- Technical
- Relative Strength Index (RSI)
- CGNT 44.61
- TRVI 53.13
- Support Level
- CGNT $8.15
- TRVI $6.93
- Resistance Level
- CGNT $8.81
- TRVI $9.92
- Average True Range (ATR)
- CGNT 0.32
- TRVI 0.76
- MACD
- CGNT -0.02
- TRVI 0.11
- Stochastic Oscillator
- CGNT 21.83
- TRVI 37.96
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.